Table 3 Relative risks of recurrence and death according to clinicopathological parameters and RBM3 expression
Relative risk of recurrence | Relative risk of death | |||||
|---|---|---|---|---|---|---|
Univariate | Multivariate | Univariate | Multivariate | |||
n(events) | RR(95%CI | RR(95%CI | n(events) | RR(95%CI) | RR(95%CI) | |
Age | ||||||
Continuous | 255(47) | 1.01(0.97-1.05) | 255(53) | 1.09(1.04-1.13) | 1.07(1.02-1.12) | |
Gender | ||||||
Female | 132(21) | 1.00 | 132(18) | 1.00 | 1.00 | |
Male | 123(26) | 1.51(0.85-2.69) | 2.60(1.47-4.61) | 2.37(1.22-4.57) | ||
Clark level | ||||||
II | 93(5) | 1.00 | 1.00 | 93(13) | 1.00 | |
III | 103(21) | 4.39(1.65-11.65) | 1.93(0.51-7.26) | 103(21) | 1.70(0.85-3.40) | |
IV-V | 51(21) | 9.99(3.76-26.55) | 1.02(0.24-4.34) | 51(18) | 3.04(1.49-6.22) | |
Breslow | ||||||
Continuous | 248(47) | 1.07(1.03-1.11) | 248(53) | 1.07(1.03-1.12) | ||
Subtype | ||||||
SSM, LMM, Other | 195(22) | 1.00 | 195(30) | 1.00 | 1.00 | |
Nodular | 53(24) | 5.63(3.15-10.08) | 53(22) | 3.86(2.21-6.74) | 2.32(1.20-4.94) | |
Ulceration | ||||||
No | 213(30) | 1.00 | 214(35) | 1.00 | 1.00 | |
Yes | 35(16) | 5.80(3.12-10.77) | 35(17) | 6.29(3.46-11.45) | 3.52(1.63-7.61) | |
Lymphocytic | ||||||
infiltrate | ||||||
0-1 | 72(20) | 1.00 | 72(22) | 1.00 | 1.00 | |
2-3 | 176(76) | 0.43(0.24-0.78) | 176(30) | 0.46(0.26-0.79) | 0.55(0.30-1.00) | |
Clinical stage | ||||||
I | 179(12) | 1.00 | 1.00 | 179(22) | 1.00 | |
II-IV | 28(13) | 15.02(6.39-35.30) | 7.36(2.47-21.47) | 28(11) | 6.48(3.05-13.73) | |
Mitotic count | ||||||
< 1/mm2 | 131(7) | 1.00 | 1.00 | 131(17) | 1.00 | |
> = 1/mm2 | 122(40) | 7.99(3.56-17.80) | 2.86(0.96-8.47) | 122(36) | 1.26(1.19-1.34) | |
Vascular invasion | ||||||
No | 232(35) | 1.00 | 1.00 | 232(42) | 1.00 | 1.00 |
Yes | 14(11) | 9.25(4.67-18.35) | 3.40(1.60-7.20) | 14(9) | 4.88(2.37-10.08) | 3.81(1.62-8.97) |
RBM3 intensity | ||||||
0-2 | 95(24) | 1.00 | 1.00 | 95(29) | 1.00 | 1.00 |
3 | 120(20) | 0.50 (0.27-0.91) | 0.87(0.46-1.66) | 120(20) | 0.36(0.20-0.64) | 0.33(0.18-0.61) |